2.07
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ESPR Giù?
Forum
Previsione
Frazionamento azionario
Esperion Therapeutics Inc Borsa (ESPR) Ultime notizie
What MACD signals say about Esperion Therapeutics Inc.Chart Signals & Verified Technical Signals - Newser
Can Esperion Therapeutics Inc. Regain Momentum After BreakdownJuly 2025 Rallies & Safe Entry Trade Reports - beatles.ru
What earnings revisions data tells us about Esperion Therapeutics Inc.Quarterly Profit Review & Real-Time Buy Signal Notifications - Newser
Real time scanner hits for Esperion Therapeutics Inc. explainedJuly 2025 Fed Impact & Fast Entry High Yield Stock Tips - Newser
Esperion Therapeutics Inc. stock outlook for YEARWeekly Volume Report & Real-Time Market Sentiment Reports - Newser
Is a relief rally coming for Esperion Therapeutics Inc. holdersTrade Signal Summary & Daily Profit Maximizing Tips - Newser
Wall Street Zen Upgrades Esperion Therapeutics (NASDAQ:ESPR) to "Hold" - MarketBeat
Esperion Delays Q2 2025 Financial Report Filing - MSN
Competitive Positioning of Esperion Therapeutics Inc.: Is It Leading or LaggingFree Intraday Trend Analysis for Fast Gains - Newser
Published on: 2025-08-10 18:32:11 - beatles.ru
FY2025 EPS Estimates for ESPR Boosted by Cantor Fitzgerald - Defense World
Esperion Therapeutics Inc. At Decision Level — Rebound or ResistanceExpert Verified Stock Trade Ideas Backed by Data - beatles.ru
ESPR's Q2 Earnings & Revenues Trump Estimates, Stock Rises - MSN
Esperion Therapeutics (NASDAQ:ESPR) Upgraded to Hold at Wall Street Zen - Defense World
HC Wainwright Issues Positive Outlook for ESPR Earnings - Defense World
Published on: 2025-08-08 10:01:24 - beatles.ru
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) for New Employees - AInvest
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Esperion Grants 73,500 RSUs with 4-Year Vesting Schedule to Attract Top Talent - Stock Titan
Esperion rises after revenue beat, Q1 profitability expectation - MSN
Esperion Therapeutics’ Earnings Call Highlights Growth - The Globe and Mail
Esperion (ESPR) Q2 Revenue Jumps 12% - AOL.com
Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates - MSN
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q2 2025 Earnings Call Transcript - Insider Monkey
Esperion expects sustainable profitability in Q1 2026 as double-digit growth continues - MSN
Esperion Therapeutics: Q2 Earnings Snapshot - New Haven Register
What institutional flow reveals about Esperion Therapeutics Inc.Long-Term Stock Growth Forecast Insights - Newser
Esperion Therapeutics Inc (ESPR) Q2 2025 Earnings Call Highlights: Strong US Net Product ... By GuruFocus - Investing.com Canada
Esperion Therapeutics Reports Strong Q2 2025 Growth - TipRanks
Esperion Therapeutics Q2 2025 Earnings Call Transcript - MarketBeat
Will Esperion Therapeutics Stock Surge Sustain? - StocksToTrade
Esperion's Q2 2025 Earnings Call: Unpacking Key Contradictions in Market Access, Growth Strategies, and Revenue Projections - AInvest
Transcript : Esperion Therapeutics, Inc., Q2 2025 Earnings Call, Aug 05, 2025 - MarketScreener
Esperion Therapeutics, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:ESPR) - Seeking Alpha
Earnings call transcript: Esperion Therapeutics Q2 2025 beats forecasts, stock rises - Investing.com Canada
Earnings call transcript: Esperion Therapeutics Q2 2025 beats forecasts, stock rises By Investing.com - Investing.com South Africa
Esperion Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Esperion Therapeutics Q2 Earnings: Narrower Loss and Revenue BeatNews and Statistics - IndexBox
Esperion Reports 12% Revenue Growth in Q2 2025 with Significant Increases in U.S. Product Sales and Settlements with ANDA Filers - Quiver Quantitative
Esperion Therapeutics Q2 revenue up 12%, operating profit beats estimates - MarketScreener
Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Esperion Reports Record 42% Revenue Growth, Secures Patent Protection Until 2040 in Breakthrough Quarter - Stock Titan
How many analysts rate Esperion Therapeutics Inc. as a “Buy”Discover top stock picks for aggressive growth - Jammu Links News
Is Esperion Therapeutics Inc. a good long term investmentAchieve rapid financial growth with expert help - Jammu Links News
What are the latest earnings results for Esperion Therapeutics Inc.Free Market Dynamics Reports - Jammu Links News
What are the technical indicators suggesting about Esperion Therapeutics Inc.Strong return on investment - Jammu Links News
Should I hold or sell Esperion Therapeutics Inc. stock in 2025Rapid wealth multiplication - Jammu Links News
Is Esperion Therapeutics Inc. stock overvalued or undervaluedAchieve breakthrough performance with smart picks - Jammu Links News
Is Esperion Therapeutics Inc. a growth stock or a value stockFree Stock Chart Pattern Guide - Jammu Links News
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):